靶向治疗在白癜风中的研究进展.

Vitiligo is a common acquired depigmentation disorder characterized by the loss of melanocytes in the skin, hair, and mucous membranes. Its characteristics of difficulty in re-pigmentation and easy recurrence are great challenges for vitiligo treatment. At present, vitiligo has been clearly classified as an autoimmune disease with a complex pathogenesis involving genetic and environmental factors, oxidative stress and autoimmune responses that synergistically promote the loss of melanocytes. With the in-depth understanding of the pathogenesis of vitiligo, a large number of clinical trials have been carried out for targeted therapy of key small molecules, cell subsets, and immune-related signaling pathways in vitiligo. Targeted therapy will become the mainstream in the treatment of vitiligo in the future. Research progress of targeted therapy for tissue resident memory T cells (TRM) pathway, JAK-STAT pathway, and WNT/β-catenin pathway in vitiligo. [ABSTRACT FROM AUTHOR]